PMID- 31035648
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 8
IP  - 5
DP  - 2019 Apr 29
TI  - New Generation Cardiac Contractility Modulation Device-Filling the Gap in Heart 
      Failure Treatment.
LID - 10.3390/jcm8050588 [doi]
LID - 588
AB  - (1) Background: Heart failure (HF) is a major cause of morbidity and mortality 
      throughout the world. Despite substantial progress in its prevention and 
      treatment, mortality rates remain high. Device therapy for HF mainly includes 
      cardiac resynchronization therapy (CRT) and the use of an implantable 
      cardioverter-defibrillator (ICD). Recently, however, a new device therapy-cardiac 
      contractility modulation (CCM)-became available. (2) Aim: The purpose of this 
      study is to present a first case-series of patients with different clinical 
      patterns of HF with a reduced ejection fraction (HFrEF), supported with the 
      newest generation of CCM devices. (3) Methods and results: Five patients with a 
      left ventricular ejection fraction (LVEF) </= 35% and a New York Heart Association 
      (NYHA) class >/= III were supported with CCM OPTIMIZER((R)) SMART IPGCCMX10 at our 
      clinic. The patients had a median age of 67 +/- 8.03 years (47-80) and were all 
      males-four with ischemic etiology dilated cardiomyopathy. In two cases, CCM was 
      added on top of CRT (non-responders), and, in one patient, CCM was delivered 
      during persistent atrial fibrillation (AF). After 6 months of follow-up, the LVEF 
      increased from 25.4 +/- 6.8% to 27 +/- 9%, and the six-minute walk distance increased 
      from 310 +/- 65.1 m to 466 +/- 23.6 m. One patient died 47 days after device 
      implantation. (4) Conclusion: CCM therapy provided with the new model 
      OPTIMIZER((R)) SMART IPG CCMX10 is safe, feasible, and applicable to a wide range 
      of patients with HF.
FAU - Tint, Diana
AU  - Tint D
AD  - Faculty of Medicine, Transilvania University & ICCO Clinics, Bd. Eroilor nr.29, 
      500036 Brasov, Romania. dianatint@gmail.com.
AD  - Sorin Micu, ICCO Clinics, Str. Scolii nr.8, 500059 Brasov, Romania. 
      dianatint@gmail.com.
FAU - Florea, Roxana
AU  - Florea R
AD  - Department of Neuroscience, Physiology and Pharmacology, University College 
      London, London WC1E 6BT, UK. 16@ucl.ac.uk.
FAU - Micu, Sorin
AU  - Micu S
AD  - Sorin Micu, ICCO Clinics, Str. Scolii nr.8, 500059 Brasov, Romania. 
      micu_sorin@yahoo.com.
LA  - eng
PT  - Journal Article
DEP - 20190429
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC6572164
OTO - NOTNLM
OT  - cardiac contractility modulation
OT  - cardiac devices
OT  - device implantation
OT  - heart failure
COIS- The authors declare no conflict of interest.
EDAT- 2019/05/01 06:00
MHDA- 2019/05/01 06:01
PMCR- 2019/04/29
CRDT- 2019/05/01 06:00
PHST- 2019/04/04 00:00 [received]
PHST- 2019/04/23 00:00 [revised]
PHST- 2019/04/26 00:00 [accepted]
PHST- 2019/05/01 06:00 [entrez]
PHST- 2019/05/01 06:00 [pubmed]
PHST- 2019/05/01 06:01 [medline]
PHST- 2019/04/29 00:00 [pmc-release]
AID - jcm8050588 [pii]
AID - jcm-08-00588 [pii]
AID - 10.3390/jcm8050588 [doi]
PST - epublish
SO  - J Clin Med. 2019 Apr 29;8(5):588. doi: 10.3390/jcm8050588.